Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06564805
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-19
Brief Title:
Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The efficacy of two intralesional treatment modalities for alopecia areata will be determined Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp with an extension of less than 50 will be included A comparison will be made between the effectiveness of intralesional Triamcinolone standard first-line treatment and intralesional Candida albicans antigen with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None